🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

SGLT2i effects in CV outcome trials may stem from adipose tissue impact: ⏫upregulate genes related to browning of white adipose tissue 🔁influence adipocyte size and fatty acid oxidation ⏬reduce oxidative stress Dive into this #CardiovascularDiabetology review👇 to explore

A potential protective role of epicardial adipose tissue (EAT) in LV reverse remodeling (LVRR) for DCM pts? 👥Prospective study of 232 consecutive DCM pts treated w/ GDMT undergoing baseline+1 yr FU CMR. 🔥Main findings: increment in EAT parameters (pericardial and epicardial

Association of SGLT2i with mortality across the spectrum of MI: a systematic review and meta-analysis 👥5 RCTs and 4 PSM observational studies involving 26.753 pts (mean age, 63 yrs; 61.2% w/ T2DM and 52.1% w/ HF), divided into early and delayed treatment trials (60.4% vs 39.6%

A new kid in town: Cardiovascular Diabetology - Endocrinology Reports! communities.springernature.com/posts/a-new-ki… We’d like to introduce Cardiovascular Diabetology’s new open-access companion journal Cardiovascular Diabetology - Endocrinology Reports.👇 clindiabetesendo.biomedcentral.com 🧬 Exploring

📊Emerging evidence highlights the prognostic value of SHR! 🔥Elevated SHR = ⬆️ risk of all-cause mortality post-MI & stroke. 🎯Should we target SHR instead of absolute glucose in interventions? ...More research is needed to define reference values & explore relative

Obesity isn't just a weight issue - it's reshaping how we diagnose heart failure. 🚨 A new meta-analysis reveals that a 1-unit BMI increases HFpEF risk by 34%! 📊 Yet, standard diagnostics fail in obesity. Time for an obesity-adjusted HFpEF score? Read more on

I am excited to be part of this paper: "Targeting the SARS-CoV-2 reservoir in long COVID" by Amy Proal, PhD Michael Peluso, MD and team, describing clinical trial recommendations for long COVID PolyBio thelancet.com/journals/lanin…

👥Systematic meta-analysis of 10 RCTs (>22,000 pts - 51.2% w/T2DM) to determine the impact of SGLT2i in pts w/ recent or previous MI. 🗓️Mean age 62 yrs; median FU was 21 months. Main findings: 💥HF hospitalization rates were ⬇️in pts on SGLT2i compared with placebo (RR 0.77;

👥Retrospective cohort study of Kidney transplant recipients (KTRs) with T2DM with 1:1 Propensity Score Matching (PSM) -> 💊GLP-1 RAs vs no-GLP-1 RAs. 📊Primary outcome: all-cause mortality Secondary outcomes: MACEs and major adverse kidney events (MAKEs). 💥In KTRs with

🌍World Obesity Day 2025! 🔎Highlighting the Role of Perivascular Adipose Tissue 🔥It's crucial to recognize the pivotal role of Perivascular Adipose Tissue in obesity-related cardiovascular diseases and its potential as a target for innovative interventions!🫀

👥84,656 individuals from the UK Biobank w/ validated accelerometry data and no T2DM were included. 🤸‍♂️Data on physical activity (PA) was collected using the Axivity AX3 wrist-based triaxial accelerometer worn for 1week. Participants were categorized into 3 PA patterns: -

🎯 To evaluate whether baseline PCATa predicts changes in plaque composition/burden over 12 months in DM pts. 👥Prospective longitudinal study including 200 T2DM pts, without symptoms or known CAD (mean age 61 ± 9.4 yrs, 72% male). 📌High PCATa levels were determined using the

🎯To explore the incremental predictive value of liver fat fraction (LFF) on MACE occurrence in T2DM pts. 👥265 T2DM pts w/ suspected CAD undergoing CCTA+upper abdominal dual-layer spectral detector computed tomography (SDCT) examinations within a 7-day interval. 📊 Elevated

🩸Diabetes is on the rise...This review explores how exercise & diet can be powerful tools against diabetic cardiomyopathy (DCM), offering hope beyond meds💊. cardiab.biomedcentral.com/articles/10.11… 👨‍🍳Diet shows both beneficial and adverse impacts on cardiac metabolism. 🏃‍♀️Exercise regimens

🎯To evaluate the cardiorenal protective effects of dapagliflozin in T2DM pts w/ CCS undergoing PCI. 👥Cross-sectional analysis of 1:1 PSM pts: 176 dapagliflozin vs. 176 control from a tertiary hospital undergoing PCI (January 2018 - March 2022). 📊 After adjusting for

🎯To assess cardiovascular, metabolic, and renal effects of combination therapy w/ GLP-1RA+SGLT2i compared to SGLT2i alone. 👥Komodo’s Healthcare Map (2017- 2023) including 100,455 people in the combination GLP-1RA+SGLT2i group and 339,540 people in the SGLT2i alone group,

👉Pts with both AS and DM face challenges arising from the interaction between the 2 conditions. 🎯To investigate the effects of DM on the LV remodelling in AS patients, specifically focusing on the inflammatory response and oxidative stress. 👥 LV myocardial biopsies were

🚨We're thrilled to launch Cardiovascular Diabetology’s #KnowTheAuthors project - giving visibility to the brilliant minds behind the science! 🎥 First up: Maria Barranco-Altirriba presents key insights from her study on lipidomics and subclinical carotid atherosclerosis in T2D

🎯To evaluate the impact of #SGLT2i on the risk of acute kidney injury (AKI) in #T2DM pts w/ severe #AS undergoing #TAVI. 👥 Multicenter Registry of consecutive pts stratified by the presence of CKD and anti-diabetic therapy (2021-2024). 🔥Our main findings were: - SGLT2i

🔥Proud to share that #CardiovascularDiabetology has achieved a new Impact Factor of 10.6 - its highest since 2009 - reinforcing its position among the leading journals in the Cardiovascular and Endocrinology & Metabolism fields. 🎯The journal now ranks 14th out of 230 in the